Cerebral microangiopathy may progress slowly and begin to manifest massive cognitive impairment when a certain brain damage threshold is reached, or more dramatically when inciting events such as infection with the SARS-CoV2 virus occur. Evidence-based therapeutic interventions for post-COVID-19 cognitive impairment have not yet been developed, and clinicians must rely on their own assumptions to help patients. Due to the anti-inflammatory mechanism of action and effectiveness in the treatment of cognitive impairment, as well as good tolerability, the combination drug vinpocetine+piracetam was proposed as a means of correcting cognitive symptoms after COVID-19. The effect of this drug on cognitive function and systemic inflammation, tested by inflammatory markers, was demonstrated in the presented clinical case report.

Keywords: vinpocetine+piracetam, inflammatory markers of endothelial dysfunction, COVID-19, cerebral microangiopathy, cognitive impairment